These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria. Vanheel H; Carbone F; Valvekens L; Simren M; Tornblom H; Vanuytsel T; Van Oudenhove L; Tack J Am J Gastroenterol; 2017 Jan; 112(1):132-140. PubMed ID: 27958284 [TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia. Hojo M; Nagahara A; Asaoka D; Takeda T; Izumi K; Matsumoto K; Ueyama H; Shimada Y; Matsumoto K; Nojiri S; Watanabe S Digestion; 2017; 96(1):5-12. PubMed ID: 28605740 [TBL] [Abstract][Full Text] [Related]
6. Postprandial distress syndrome: stratification and management. Van Den Houte K; Carbone F; Tack J Expert Rev Gastroenterol Hepatol; 2019 Jan; 13(1):37-46. PubMed ID: 30791841 [TBL] [Abstract][Full Text] [Related]
7. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Yamawaki H; Futagami S; Kawagoe T; Maruki Y; Hashimoto S; Nagoya H; Sato H; Kodaka Y; Gudis K; Akamizu T; Sakamoto C; Iwakiri K Neurogastroenterol Motil; 2016 Jul; 28(7):1037-47. PubMed ID: 26920949 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of acotiamide on postprandial distress syndrome and epigastric pain syndrome depending on the estimated gastric acid secretion level. Suzuki T; Ohba R; Kataoka E; Kudo Y; Zeniya A; Segawa D; Oikawa K; Odashima M; Saga T; Kuramitsu T; Sasahara H; Yoneyama K; Tomita T; Shimodaira Y; Iijima K J Neurogastroenterol Motil; 2022 Jan; 28(1):53-61. PubMed ID: 34366297 [TBL] [Abstract][Full Text] [Related]
9. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kawarai Lefor A; Yamamoto H J Med Invest; 2016; 63(3-4):230-5. PubMed ID: 27644564 [TBL] [Abstract][Full Text] [Related]
10. Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria. Tack J; Talley NJ Nat Rev Gastroenterol Hepatol; 2013 Mar; 10(3):134-41. PubMed ID: 23399526 [TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial. Tack J; Pokrotnieks J; Urbonas G; Banciu C; Yakusevich V; Bunganic I; Törnblom H; Kleban Y; Eavis P; Tsuchikawa M; Miyagawa T Neurogastroenterol Motil; 2018 Jun; 30(6):e13284. PubMed ID: 29315999 [TBL] [Abstract][Full Text] [Related]
12. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. Matsunaga Y; Tanaka T; Yoshinaga K; Ueki S; Hori Y; Eta R; Kawabata Y; Yoshii K; Yoshida K; Matsumura T; Furuta S; Takei M; Tack J; Itoh Z J Pharmacol Exp Ther; 2011 Mar; 336(3):791-800. PubMed ID: 21123674 [TBL] [Abstract][Full Text] [Related]
13. Drugs under development for the treatment of functional dyspepsia and related disorders. Tack J; Masuy I; Van Den Houte K; Wauters L; Schol J; Vanuytsel T; Vandenberghe A; Carbone F Expert Opin Investig Drugs; 2019 Oct; 28(10):871-889. PubMed ID: 31566013 [No Abstract] [Full Text] [Related]
14. Current and emerging therapeutic options for the management of functional dyspepsia. Vandenberghe A; Schol J; Van den Houte K; Masuy I; Carbone F; Tack J Expert Opin Pharmacother; 2020 Feb; 21(3):365-376. PubMed ID: 31899982 [No Abstract] [Full Text] [Related]